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Abstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can
affect various parts of the eye or the surrounding tissues. Non-steroidal anti-inflammatory drugs
(NSAIDs) such as ibuprofen, are commonly used to treat ocular inflammation in the form of eye-drops.
However, their bioavailability in ocular tissues is very low (less than 5%). Therefore, drug delivery
systems such as biodegradable polymeric PLGA nanoparticles constitute a suitable alternative to
topical eye administration, as they can improve ocular bioavailability and simultaneously reduce drug
induced side effects. Moreover, their prolonged drug release can enhance patient treatment adherence
as they require fewer administrations. Therefore, several formulations of PLGA based nanoparticles
encapsulating dexibuprofen (active enantiomer of Ibuprofen) were prepared using the solvent
displacement method employing different surfactants. The formulations have been characterized and
their interactions with a customized lipid corneal membrane model were studied. Ex vivo permeation
through ocular tissues and in vivo anti-inflammatory efficacy have also been studied.
Keywords: dexibuprofen; drug delivery system; nanoparticles; PLGA
1. Introduction
Ibuprofen is a widely used analgesic, antipyretic and anti-inflammatory drug [1]. Dexibuprofen
(DXI) is the single pharmacologically effective enantiomer of racemic ibuprofen [2]. In the dose ratio of
1:0.5 (racemic ibuprofen vs. DXI), several pain models show that DXI is as effective, or superior to
racemic ibuprofen. In addition, DXI has demonstrated comparable efficacy to diclofenac, naproxen
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and celecoxib [2]. Therefore, it constitutes a suitable candidate for ocular drug delivery in order to
treat ocular inflammation. DXI has shown favorable tolerability when compared to other NSAIDs
but still shows some adverse effects associated with this family. Moreover, eye drops often require
frequent instillations, due to the rapid and extensive pre-corneal loss caused by drainage through the
nasolacrimal duct, and by the non-productive absorption after corneal permeation and blinking [3].
Therefore, in order to reduce DXI adverse effects and extend its release by decreasing the number of
instillations required, DXI loaded nanoparticles administered as eye drops may represent a viable
solution to the problem.
Nanocarriers are particularly attractive as they provide protection to the drug, increase drug
efficacy, permeate physiological barriers and decrease toxicity [1]. In this sense, biodegradable
nanoparticles made of poly-D,L-lactic-co-glycolic acid (PLGA) may represent a suitable candidate to
encapsulate DXI and deliver it slowly into the target tissue [4]. In addition, PLGA has been approved
by the Food and Drug Administration and is one of the most successful biodegradable polymers [3–6].
Moreover, PEG has been widely used to reduce the clearance of PLGA nanoparticles (NPs) and it has
been demonstrated that PEG coatings shield the surface from aggregation, opsonization, phagocytosis
and prolong nanoparticles systemic circulation time [5]. Poly(ethylene glycol) (PEG) is a non-ionic,
hydrophilic, polyether synthesized by polymerization of the monomer ethylene glycol and can be
obtained in a wide range of molecular weights [7,8].
For this reason, several % of PEG have been studied and compared with PLGA NPs. Additionally,
the role of various surfactants commonly used for ocular drug delivery in the formation, characterization
and efficacy of PLGA and PLGA PEG NPs have been studied. In this sense, widely used non-ionic
surfactants such as Lutrol F68 (Poloxamer 188), Tween 80® and polyvinyl alcohol (PVA) have been
studied [9].
In addition, the development of corneal membrane models able to mimic the interactions between
the cornea and the drug delivery systems is still an unmet medical need. Therefore, a corneal membrane
model has been developed mimicking the lipid structure of the corneal surface and the interactions
between the different DXI NPs. Hence, one of the aims of this study will be to develop an in vitro
corneal membrane model that is suitable to study the interactions of drugs and drug delivery systems
with their surface. The results will be correlated with the in vitro drug release of DXI from the NPs
and with the ex vivo and in vivo therapeutic efficacy. In vitro and in vivo ocular tolerance has also
been assured for all the formulations prior to in vivo experiments.
2. Materials and Methods
2.1. Preparation of Polymeric Nanoparticles
PLGA nanoparticles (NPs) containing DXI were prepared by using the solvent displacement
method [10,11]. In summary, 90 mg of PLGA (Boehringuer Ingelheim®, Ingelheim am Rhein, Germany)
and 5 mg of dexibuprofen (Amadis Chemical®, Hangzhou, Zhejiang, China) were weighed and
dissolved in 5 mL of acetone. The organic solution was added dropwise into 10 mL of an aqueous
surfactant solution at pH 3.5 under magnetic stirring. Following this, the acetone was evaporated
under reduced pressure. Various optimized concentrations of surfactants were used (PVA 0.5%, Tween
80® 0.3% and Lutrol F68 (1%). NPs prepared using PVA were centrifuged at 15,000 rpm for 30 min
in order to remove excess of PVA. Empty PLGA NPs were prepared using the same protocol but
without dexibuprofen.
2.2. Characterization of Formulations
2.2.1. Particle Size, Zeta Potential and Polydispersity (PI)
Particle size and polydispersity index (PI) were determined by dynamic light scattering using a
Zetasizer nano ZS (Malvern instruments, IESMAT, Alcobendas, Madrid, Spain) at 25 ◦C and scattering
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angle of 90 ◦C. Zeta potential (ZP) was determined by electrophoresis laser-Doppler using the same
instrument. Samples were previously diluted 1:10 (v/v) in water and the assays were carried out
in triplicate.
2.2.2. Entrapment Efficiency (EE)
The amount of DXI entrapped in the NPs was calculated indirectly using/Equation (1)/[1]. DXI
NPs were diluted 1:100 (v/v) in water and filtration-centrifugation at 14,000 rpm for 30 min was
carried out. The amount of free DXI in the supernatant was determined by high-performance liquid
chromatography (HPLC).
EE (%) =
Total amount o f DXI − Free DXI
Total amount o f DXI
× 100 (1)
HPLC quantification was carried out 220 nm using a Kromasil®C18 (5 µm, 150 mm × 4.6 mm
with a mobile phase 80:20 (methanol: orthophosphoric acid 0.05%) [11].
2.2.3. Transmission Electron Microscopy
Transmission electron microscopy (TEM) was used to investigate the morphology of the DXI NPs
on a Jeol 1010 (Jeol USA, Dearborn Road, Peabody, MA 01960, USA). Copper grids were activated
with UV light and samples were diluted (1:10) and placed on the grid surface to visualize the particles.
Samples were previously subjected to negative staining with uranyl acetate (2%) [12].
2.2.4. Interaction Studies
Differential scanning calorimetry (DSC) analysis was performed using a DSC 823e System
Mettler-Toledo, Barcelona, Spain. A pan with indium (purity ≥99.95%; Fluka, Switzerland) was used
to check the calibration of the calorimetric system. An empty pan served as a reference. The DSC
measurements were carried out in all DXI NPs formulations using a heating ramp from 25 to 105 ◦C at
10 ◦C/min in a nitrogen atmosphere. Data was evaluated using the Mettler STARe V 9.01 dB software
(Mettler-Toledo, Barcelona, Spain) [5].
X-ray spectroscopy (XRD) was used to analyze the amorphous or crystalline state of the samples
(centrifuged DXI NPs). Samples were sandwiched between 3.6 µm polyester films and exposed to
CuKα radiation (45 kV, 40 mA, λ = 1.5418 Å) in the range (2θ) of 2–60◦ with a step size of 0.026◦ and a
measuring time of 200 s per step [13].
Fourier transform infrared (FTIR) spectra of DXI NPs were obtained using a Thermo Scientific
Nicolet iZ10 with an ATR diamond and DTGS detector (Barcelona, Spain) [12].
2.3. In Vitro Release Study
In order to study the in vitro drug release of DXI from the drug delivery systems, a bulk-equilibrium
reverse dialysis bag technique was applied [11]. This technique is based on the dispersion of the
colloidal suspension in the dialysis medium accomplishing sink conditions.
The release medium was composed of a buffer solution (PBS 0.1 M, pH 7.4) and 14 dialysis sacs
containing 0.5 mL of PBS were previously immersed. A volume of 7 mL of free DXI or DXI loaded NPs
were added to 136 mL of the dissolution medium. The assay was carried out by triplicate comparing
the formulations. Release kinetic experiments were performed at a fixed temperature of 32 ◦C (ocular
surface temperature) under constant magnetic stirring (n = 6/group). At predetermined time intervals,
dialysis sacs were withdrawn from the stirred release solution and the volume was replaced by 0.5 mL
of PBS. The content of the sacs at each time point was evaluated and data were adjusted to the most
common kinetic models [14].
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2.4. Sterilization Using Gamma Radiation
DXI NPs were sterilized using gamma irradiation using 60Co at a dose of 25 kGy (Aragogamma,
Barcelona, Spain) [15]. According to the European Pharmacopoeia, 25 kGy represents the adequate
absorbed dose for the purpose of sterilizing pharmaceutical products when bioburden is not known.
Furthermore, it is considered a standard γ-irradiation dose recommended for terminal sterilization
of medical products that maintain a valid sterility assurance level of 10−6 [16].
2.5. In Vitro Ocular Irritation Assay: HET-CAM
In vitro ocular irritation assay was carried out in order to measure the potential irritation properties
of the developed formulations. This assay was based on the INVITTOX 15 protocol [17].
During the test, the direct observation of the irritant effects (bleeding, vasoconstriction and
coagulation) in the chorioallantoic membrane (CAM) of an embryonated egg (10 days) induced by
application of 300 µL of the studied formulation, was performed during the first 5 min [18]. In the
experimental procedure, fertilized and incubated eggs during 10 days were used. These eggs (from
the farm G.A.L.L.S.A, Tarragona) were placed in the incubator at controlled temperature (37.8 ◦C) and
humidity (50–60%). A series of controls were performed: SDS 1% (positive control for slow irritation), 0.1
N NaOH (positive control for fast irritation) and NaCl 0.9% (negative the injury occurred (n = 6/group).
Data were analyzed as the Ocular irritation index (OII) mean ± SD was calculated by applying
Equation (2). OII can be grouped into four categories [11].
OII =
5(301−H)
300
+
7(301−V)
300
+
9(301−C)
300
(2)
Meaning, H hemorrhage, V vasoconstriction and C coagulation phenomena.
2.6. In Vivo Ocular Irritation Assay
In vivo ocular tolerance was measured using primary eye irritation test of Draize et al. using
New Zealand albino rabbits of 2.5 kg from San Bernardo farm (Navarra) [19]. This test was performed
according to the Ethical Committee for Animal Experimentation of the UB and current legislation
(Decret 214/97, Gencat). Instilled in the conjunctival sac of the eye was 50 µL of sample and the
appearance of irritation was observed at the time of administration and after 1 h. The evaluation was
undertaken by direct observation of the anterior segment of the eye calculating the injuries of the
conjunctiva, iris and cornea. The punctuation applied has been described elsewhere [20] and the ocular
irritation index has been calculated according to Equation (3).
OII = Corneal (A × B × 5) + Iris (A× 5) +Conjunctiva (A+ B+C)·2 (3)
2.7. In Vitro Customized Corneal Membrane Model and Interactions Study
2.7.1. Langmuir Monolayers
Langmuir monolayers were obtained by spreading a lipid solution at the air/water interface.
The subphase was a TRIS buffer solution (10 mM, pH 7.4). To prepare the spreading solution,
appropriate amounts of ACMM (adult corneal membrane model) lipid mixture were dissolved in
chloroform/methanol (2:1; final concentration 1 mM). ACMM composition was L-α-phosphatidylcholine
45%, L-α-phosphatidylethanolamine (55%), L-α-phosphatidylserine (10%); PC:PE:PS (45:55:10) at
50.4% mol/mol supplemented with sphingomyelin (25%) and cholesterol (75%) SM:CHOL (25:75) at
49.6% mol/mol. All lipids were from Avanti®Polar Lipids, (Alabaster, AL, USA). A Langmuir film
balance (Biolin Scientific, Manchester, United Kingdom) equipped with a Whilhelmy filter plate and
a Teflon barrier was used to obtain the surface-pressure (pi-A) isotherms at the air water interface.
The Teflon barrier (total area: 590 cm2) was placed on a vibration isolation table and enclosed in an
environment protection cabinet. Chloroform/methanol lipid solution was spread dropwise on the
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subphase and before compression, 15 min were allowed in order to ensure total evaporation of the
solvent. The reduction of the area was carried out by compression of monolayer at a constant rate of
10 cm2·min−1 at room temperature. Measurement accuracy was 0.1 mN·m−1.
2.7.2. Preparation of Fluorescent Labeled LUVs
Fluorescent labeled large unilamellar vesicles (LUVs) were obtained by the extrusion method
as described elsewhere [21]. Briefly, the lipid mixture used to produce ACMM was dissolved in a
chloroform/methanol (2:1 v/v) mixture at 10 mM with a 0.1 mM of di-8-ANEPPS fluorescent probe
(4-[2-[6-(dioctylamino)-naphthalenyl]ethenyl]-1-(3-sulphopropyl)-pyridinium) from Molecular Probes
Inc. (Invitrogen, Cralsbad, CA, USA). The solvent was removed to dry in a vacuum with a rotary
evaporator and then the dried film was kept at high vacuum overnight to eliminate any residual solvent
traces. Dried film was rehydrated with a TRIS buffer solution (10 mM, pH 7.4) to obtain multilamellar
vesicles (MLVs). Large unilamellar vesicles (LUVs) were prepared by 10 freeze–thaw cycles of MLVs,
followed by the extrusion through polycarbonate filters (Nucleopore, Pleasanton, CA, USA) with 100
nm pore-size in a high-pressure system (Lipex Biomembranes, Vancouver, Canada). To assure LUVs
formation, the temperature was maintained at 60 ◦C (above the transition temperature of lipids).
2.7.3. Interaction of DXI NPs with Model Membranes
pi-A isotherm experiments were carried out to ascertain the effect that NPs have when they make
contact with the membrane model. Firstly, a lipid monolayer was obtained spreading 70 µL of 1 mM
ACMM solution and after the equilibrium (at constant surface pressure, pi = 0 mN·m−1) was reached at
35 µL of 1 mg/mL DXI NPs was spread on the lipid monolayer. The initial surface pressure increased by
20 mN·m−1, when equilibrium (constant surface pressure at 20 mN·m−1) was achieved. The monolayer
compression continued until the collapse pressure (pic) was reached. There are some useful parameters
to characterize the pi-A curves; pic is the maximum surface pressure that can be achieved without
breaking the film and the compressibility modulus (C−1s ), which is a measure of the monolayer elasticity
and characterizes the phase state of lipid films. It was calculated using Equation (4):
C−1s = −A
(
∂pi
∂A
)
(4)
where A is the area occupied and pi is the surface pressure. Values of C−1s ranges from 12.5 to 50 mN m−1
for liquid-expanded phase and from 100 to 250 mN·m−1 aproximately for the liquid-condensed
phase [22–24].
Dipole potential measures were performed by fluorescence spectroscopy. When NPs bind
to penetrate the membrane, this causes changes in the membrane dipole potential, which can be
determined by monitoring the fluorescence intensity excitation spectral shifts of the di-8-ANEPPS
probe [25–27]. Fluorescence excitation spectra were recorded using Photon Technology International
AC-10 spectrofluorometer (London, ON, Canada) at an emission wavelength was 580 nm. The
measurement of the membrane dipole potential comes from the ratio of fluorescence intensities at
λex460 nm and λex520 nm (R = I460/I520). For interaction assays, increasing amounts of NPs suspension
(5–250 µg·mL−1) were added to 40 µL of di-8-ANEPPS labeled LUVs (200 µM lipid, 2 µM ANEPPS)
and the variation of fluorescence intensity and fluorescence ratio (R) with NPs concentration were
recorded. The normalized Rnorm was obtained by dividing the fluorescence ratio, R, obtained for a
LUVs suspension in presence of NPs with that obtained in absence of them (Ro). The data of Rnorm
(R/Ro) as a function of NPs concentration were fitted to a single binding site model Equation (5) using
GraphPad Prism software (San Diego, CA, USA) [28]:
1−Rnorm = Bmax[NPs]Kd × [NPs] (5)
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where Bmax is
(
1− RminRo
)
, [NPs] is the NPs concentration (µg/mL) and Kd is the apparent dissociation constant.
2.8. Prevention of In Vivo Ocular Inflammation
Prevention of ocular inflammation was assessed in vivo (n = 6/group) using New Zealand Albino
rabbits. In order to carry out this assay, 50 µL of the developed formulations were applied to the
conjunctival sac of the eye using the left eye as a control. After 30 min, 50 µL of sodium araquidonate
0.5% were applied. Inflammation was measured every 30 min and the ocular inflammation score (OII)
was calculated as reported elsewhere [29].
2.9. Ex Vivo Ocular Permeation
In order to study the drug release from the NPs, Franz diffusion cells were used. Corneal and
scleral tissue of male New Zealand rabbits (2.5–3 kg) was removed under veterinary supervision,
and according to the Ethics Committee of Animals Experimentation from the University of Barcelona
(CEEA-UB). The rabbits were anesthetized with intramuscular administration of ketamine HCl
(35 mg/kg) and xylazine (5 mg/kg) and euthanized by an overdose of sodium pentobarbital (100 mg/kg)
administered through marginal ear vein under deep anesthesia. The cornea and sclera were excised
and immediately transported to the laboratory in artificial tear solution [30].
The tissues were placed in the cells with a separating membrane with a diffusional area of 0.64 cm2.
The developed nanoparticles were placed on the donor compartment (0.2 mL DXI NPs) and the drug
release from the basolateral compartment was studied at different timepoints by removing 300 µL of
sample and replacing it with free PBS. The cumulative DXI amount permeated was calculated, at each
time point, from the DXI amount in the receiving medium.
3. Results and Discussion
3.1. Characterization of the Nanocarriers
The formulations were characterized as seen in Table 1. The formulations were optimized using
PLGA-PEG 5% for each surfactant used (Lutrol, PVA and Tween80®). Therefore, four different
polymers and three of the most commonly used surfactants were assessed. Different PLGA-PEG
triblocks were used.
Table 1. Characterization of the different formulations developed.
Formulation
Number
Polymer
Used Surfactant
Average
Size (nm)
Polydispersity
Index (PI)
Zeta Potential
(ZP, mV) EE (%)
1
PLGA 503 H
PVA 234.1 ± 0.5 0.081 ± 0.009 −12.2 ± 1.3 93.4
2 Tween80® 146.0 ± 0.6 0.054 ± 0.008 −25.2 ± 0.6 87.5
3 Lutrol 159.5 ± 0.8 0.058 ± 0.021 −26.0 ± 0.1 85.1
4
PLGA-5%
PVA 167.1 ± 1.1 0.080 ± 0.012 −11.8 ± 0.9 95.0
5 Tween80® 138.4 ± 1.3 0.072 ± 0.015 −14.1 ± 1.1 91.5
6 Lutrol 154.2 ± 1.9 0.063 ± 0.015 −18.7 ± 1.4 93.8
7
PLGA 10%
PVA 140.9 ± 1.0 0.055 ± 0.023 −16.7 ± 0.7 99.0
8 Tween80® 119.2 ± 1.0 0.074 ± 0.008 −21.2 ± 0.6 99.2
9 Lutrol 120.7 ± 0.8 0.071 ± 0.008 −23.1 ± 1.8 91.5
10
PLGA 15%
PVA 156.4 ± 0.8 0.078 ± 0.008 −16.2 ± 0.7 92.2
11 Tween80® 143.0 ± 0.5 0.062 ± 0.006 −21.4 ± 0.8 93.4
12 Lutrol 155.2 ± 1.1 0.076 ± 0.012 −22.5 ± 0.5 94.0
As demonstrated in Table 1, all the formulations except F1 show an average size below 200 nm. In
the case of F1, the average size was slightly bigger than the other formulations and the ZP was closer
to neutrality. ZP was negative (around −15 mV) due to polymer carboxylic chain [10].
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The same phenomenon was observed in all the formulations containing PVA, obtaining lower ZP
than with the other surfactants used due to the fact that PVA would interact with PLGA chains causing
an increase in ZP [31]. Regarding the EE, it was higher than 85% in all the formulations. This confirms
that DXI was encapsulated in the polymeric matrix using all the polymers and surfactants.
3.2. DXI NPs Characterization Studies
DSC profiles of DXI show a sharp endotherm corresponding to its melting transition (data
previously published), characterized by a Tmax = 53.06 ◦C, which was not detected in DXI-PLGA-PEG
NPs [11]. This suggests that DXI formulated in PLGA or in PLGA-PEG NPs is in an amorphous
or disordered crystalline phase of a molecular dispersion or in a solid solution state in the polymer
matrix (Figure 1). Moreover, PEG masks PLGA glass transition temperature (Tg) probably due to the
plasticizing effect of PEG. This effect has also been shown to cause a reduction in the attractive forces
amongst the polymer chains leading to slight reduction in the Tg value of the polymer, which can be
observed on the thermic profile [32].Nanomaterials 2020, 10, x FOR PEER REVIEW 8 of 25 
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Figure 1. Differential scanning calorimetry (DSC) of DXI loaded nanoparticles. (A) DXI PLGA 
nanoparticles (NPs), (B) DXI PLGA 5% PEG NPs and (C) DXI PLGA 15% NPs. 
Figure 1. Differential scanning calorimetry (DSC) of DXI loaded nanoparticles. (A) DXI PLGA
nanoparticles (NPs), (B) DXI PLGA 5% PEG NPs and (C) DXI PLGA 15% NPs.
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XRD profile (Figure 2) shows that all nanoparticles possess a similar profile due to the PLGA
polymer, corresponding to an amorphous pattern and a peak at approximately 2θ = 18 ◦C is shown.Nanomaterials 2020, 10, x FOR PEER REVIEW 9 of 25 
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NPs and (C) DXI PLGA 15% PEG NPs. 
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DXI was encapsulated in the polymeric matrix. Moreover, in the case of PLGA NPs using PVA, a 
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In addition, the formulations of DXI loaded NPs were observed using TEM [34]. As can be 
observed in Figure 4, all the formulations show a spherical shape and a smooth surface. No 
differences regarding the PEG chains or between the surfactants were observed. In addition, there 
was no sign of aggregation phenomena and the average size was similar to that obtained using 
photon correlation spectroscopy. 
Figure 2. X-ray diffraction of DXI loade nanoparticl s. (A) DXI PLGA NPs, (B) DXI PLGA 5% PEG
NPs and (C) DXI PLGA 15% PEG NPs.
Moreover, no peaks corresponding with DXI are observed in any of the formulations. This
confirms DXI encapsulation into the polymeric matrix [20]. Surprisingly, in DXI PLGA Lutrol NPs, the
intensity obtained was higher than with PVA and Tween nanoparticles. The opposite phenomenon
was found when adding PEG and with PLGA 5% PEG NPs; ween shows an incre sed intensity
against the other two surfactants. Furt rmore, PLGA 15% PEG nanoparticles show a similar trend to
PLGA 5% but with a markedly increased intensity of PLGA 15% Tween NPs. In this case, PVA NPs
show an increased intensity than Lutrol. These results may indicate that in PLGA Lutrol NPs, the
surfactant favored an increased order of the matrix whereas in PEG NPs, Tween increases the order,
obtaining higher intensities [33]. This interaction of Tween and PEG was confirmed as the percentage
of PEG increase .
FTIR analysis was used to study the interactions between t e drug, the surfactant and polymer
(Figure 3). There was no evidence of strong bonds between DXI and PLGA-PEG and the surfactant.
DXI peaks (reported in previous publications) were not found in the NPs. These results meaning that
DXI was encapsulated in the polymeric matrix. Moreover, in the case of PLGA NPs using PVA, a peak
around 3400 cm−1 corresponding with PVA can be observed. This may be due to a slight amount of
PVA on the NPs surface due to the steric interaction between PVA and PLGA. PEG is probably able to
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reduce these interactions and no PVA peaks were found in the formulations using PEG. Furthermore,
PLGA exhibited intense bands at 2907 and 2950 cm−1. An intense peak at 1743 cm−1 is shown in all
DXI NPs samples, thus corresponding to the C-O stretching vibration of the carbonyl groups present
in the two monomers that form the PLGA matrix [9]. Bands obtained 1077, 1199 and 1305 cm-−1 in the
NPs are attributed to stretching vibrations of the OH group of the polymer [9].anomat ri ls 2020, 10, x FOR PEER REVIEW 10 of 25 
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Figure 3. FTIR of DXI loaded nanoparticles. (A) DXI PLGA NPs, (B) DXI PLGA 5% PEG NPs and (C) 
DXI PLGA 15% NPs. 
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In addition, the formulations of DXI loaded NPs were observed using TEM [34]. As can be
observed in Figure 4, all the formulations show a spherical shape and a smooth surface. No differences
regarding the PEG chains or between the surfactants were observed. In addition, there was no
sign of aggregation phenomena and the average size was similar to that obtained using photon
correlation spectroscopy.Nanomaterials 2020, 10, x FOR PEER REVIEW 11 of 25 
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using Tween80®; (G) DXI PLGA 10%PEG NPs using Lutrol; (H) DXI PLGA 10% PEG NPs using PV; 
(I) DXI PLGA 10% PEG NPs using Tween80®; (J) DXI PLGA15%PEG NPs using Lutrol; (K) DXI PLGA 
15% PEG NPs using PVA and (L) DXI PLGA 15% PEG NPs using Tween80® as a surfactant. 
3.3. Sterilization Using Gamma Radiation 
PLGA nanoparticles can be effectively sterilized for ocular drug delivery using gamma radiation 
[35]. However, in some cases, gamma radiation can affect physicochemical parameters of the 
formulations. For this reason, the formulations were analyzed before and after gamma radiation and 
the ratio between both was calculated. As shown in Table 2, the majority of the formulations were 
not affected by the irradiation and only PI was slightly increased in F1, which was the only 
formulation with more than 200 nm of average size. However, the ratio before and after was close to 
1 in all cases. These results were in agreement with other authors that freeze dried PLGA NPs such 
as Ramos et al. confirming that 25 KGy does not affect the physicochemical structure of DXI NPs [36]. 
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Figure 4. Transmission electron microscopy of the different formulations of nanoparticles (A) DXI
PLGA NPs using Lutrol; (B) DXI PLGA NPs using PVA; (C) DXI PLGA NPs using Tween80®; (D) DXI
PLGA5%PEG NPs using Lutrol; (E) DXI PLGA 5% PEG NPs using PVA; (F) DXI PLGA 5% PEG NPs
using Tween80®; (G) DXI PLGA 10%PEG NPs using Lutrol; (H) DXI PLGA 10% PEG NPs using PV; (I)
DXI PLGA 10% PEG NPs using Tween80®; (J) DXI PLGA15%PEG NPs using Lutrol; (K) DXI PLGA
15% PEG NPs using PVA and (L) DXI PLGA 15% PEG NPs using Tween80® as a surfactant.
3.3. Ster lization Using Ga ma Radiation
PLGA nanoparticles can b eff ctively st rilized for oc lar drug delivery using g mma
radiati n [35]. However, in ome cases, gamma radiation can affect physicochemical parameters of the
formulations. For this reason, the formulations were analyzed before and after gamma radiation and
the ratio between bot in Table 2, the majority of the formulations were not
affected by the irrad ation and only PI was slightly increased in F1, which was t e only formulation
with more than 200 nm of average size. How ver, the ratio befor and after was close to 1 in all cases.
These re ults w r in agreement with other authors that freeze dried PLGA NPs such as Ramo et al.
confirming that 25 KGy does not affect the physico hemical stru ture of DXI NPs [36].
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Table 2. Sterilization using gamma radiation (ratio between before and after sterilization).
Formulation
Number
Polymer
Used Surfactant
Average
Size Ratio
Polydispersity
Index Ratio
Zeta Potential
Ratio
EE
Ratio
1
PLGA 503 H
PVA 1.00 0.61 0.97 1.00
2 Tween80® 1.01 1.23 0.97 1.01
3 Lutrol 1.00 1.00 1.00 1.02
4
PLGA-5%
PVA 1.01 1.03 1.14 0.98
5 Tween80® 1.00 0.92 1.05 1.01
6 Lutrol 1.01 1.07 0.97 0.95
7
PLGA 10%
PVA 0.98 1.00 1.03 0.98
8 Tween80® 0.99 0.94 1.01 0.98
9 Lutrol 0.99 1.21 0.99 0.99
10
PLGA 15%
PVA 0.99 1.28 1.02 1.04
11 Tween80® 1.02 1.06 1.03 1.01
12 Lutrol 1.00 1.01 0.94 1.02
3.4. In Vitro Drug Release
The in vitro release profile of DXI from the NPs demonstrates that all the formulations have a
kinetic profile that is characteristic of prolonged drug release formulations (Table 3) [37]. As expected,
DXI free is released after 150 min. The release best fit was a one-phase association, meaning that
the release is proportional to the DXI concentration with a half-life of 29 min [38]. This fast release
implies that several administrations would be necessary in order to prevent and treat the inflammation
associated with several pathologies and associated with surgical procedures.
In all the DXI NPs, it can be observed that the profile release is slower, and two phases can
be distinguished (Figure 5). The initial rapid release lasts around 150 min in all the formulations,
associated with the drug attached to the NPs surface. After 150 min it was observed that NPs solutions
maintained a sustained drug release profile and were able to release the drug for more than 24 h
(1440 min). The drug release (Y in percentage) from the formulations was adjusted to a hyperbola
equation, Equation (6)
Y =
Bmax × t
(Kd + t)
(6)
Being the Kd half of the time when DXI that is released at equilibrium and Bmax the maximum %
of DXI released after 24 h of experiment.
According to the results showed in Table 3, PLGA nanoparticles and PLGA 5% NPs show that
the dissociation constant (Kd) decreased obtaining higher Kd from PVA > Tween80 > Lutrol F68.
These results indicate that DXI PLGA PVA NPs had a slower release when compared to the other two
surfactants [39]. The same trend was observed with PLGA 5% PEG. However, it was reversed as the %
of PEG increases and with 10% PEG all the Kd obtained with the different surfactants were similar.
In the formulations containing 15% PEG, the initial trend was reversed obtaining Kd of Lutrol F68 <
Tween80 < PVA. Therefore, as increasing the PEG concentration, PVA might probably decrease the
steric interactions with PLGA and Lutrol NPs release DXI slowly. Moreover, comparing the polymers
used, increasing the amount of PEG increased the value of Bmax irrespective of the surfactant used. In
this sense, the lower Bmax corresponded to PVA DXI loaded PLGA 15% PEG NPs.
A sustained release of DXI into the NPs was shown in all the formulations compared with the free
DXI and it would decrease the number of drug administration required by a patient.
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Table 3. Pharmacokinetic parameters of PLGA nanoparticles applied to a hyperbola equation.
Formulation Number Polymer Used Surfactant Bmax (%) Kd (min)
1
PLGA 503 H
PVA 50.6 ± 2.3 210.6 ± 24.3
2 Tween80® 46.9 ± 1.6 89.6 ± 10.1
3 Lutrol 48.7 ± 1.4 79.7 ± 7.9
4
PLGA-5%
PVA 33.5 ± 2.8 149.2 ± 35.2
5 Tween80® 40.4 ± 1.1 84.5 ± 7.6
6 Lutrol 41.6 ± 0.5 79.9 ± 3.4
7
PLGA 10%
PVA 38.5 ± 0.5 78.1 ± 3.9
8 Tween80® 43.0 ± 1.8 72.1 ± 10.9
9 Lutrol 45.1 ± 1.4 77.1 ± 8.5
10
PLGA 15%
PVA 41.4 ± 1.1 59.8 ± 6.0
11 Tween80® 44.6 ± 1.0 79.4 ± 6.3
12 Lutrol 58.3 ± 1.5 113.6 ± 9.2
3.5. Ocular Tolerance
Ocular tolerance was studied in vitro and in vivo. Hen’s egg-chorioallantoic membrane
(HET-CAM) test was applied showing that the positive controls (NaOH 1 M) resulted in severe
hemorrhage, which increased over five minutes grading this solution as a severe irritant. On the other
hand, application of the formulations to the chorioallantoic membrane did not cause irritation and
therefore, the formulations were classified as non-irritant. However, since a single in vitro test is not
able to reproduce the in vivo situation, ocular tolerance Draize tests were performed. The tests were
carried out with all DXI NPs. As an example, in Figure 6, DXI NPs containing Lutrol are shown.
In this sense, none of the developed formulations were irritant in vivo or in vitro. These results
correlate with previous studies developed using PLGA NPs [40]. These results are in agreement with
the HET-CAM test confirming the non-irritant potential of DXI loaded polymeric nanoparticles and
also the suitability of the HET-CAM test in order to mimic the in vivo irritation phenomena.
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3.6. In Vitro Interactions with a Customized Corneal Membrane Model
3.6.1. pi-A Isotherm Analysis
Figure 7 shows the pi-A curve obtained for lipid monolayer (ACMM composition) and the curves
obtained when DXI NPs were spread on the ACMM-lipid monolayer. In this case, the initial surface
pressure was increased until equilibrium (constant surface pressure) was reached. The posterior
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compression of the system showed the changes in the area until collapse pressure was achieved
(Figure 7). DXI NPs caused an expansion of the ACMM monolayer in all the cases being reflected by a
pressure shifting to the right side of the graph. The area increased depending on the surfactant used
(ATW > APVA > ALUT) as can be seen in Table 4. It shows area values at 32 mN·m−1, which is accepted
for biological membrane and bilayers pressure [41,42]. This area expansion suggests that the NPs
interact with the membranes by inserting themselves between the lipids. DXI NPs developed using
Tween as a surfactant present greater area expansion, obtaining 234.8 cm2 at 32 mN·m−1 (significantly
greater than the 169.5 cm2 obtained for ACMM). PLGA-PVA NPs and PLGA-Lutrol NPs, at the same
surface pressure, have 185.5 cm2 and 178.2 cm2 respectively suggesting a more subtle expansion than
the former. Regarding the percentage of PEG in the formulations, this affects the A values but not
significantly. However, to deeply understand this data, the compression modulus was calculated using
Equation (4).
Table 4. Surface properties of ACMM only and mixed ACMM–DXI NPs monolayers containing
different PEG concentrations; and PVA, Tween and Lutrol as surfactants.
Monolayer Composition A/cm
2
at 32 mN·m−1
C−1s /mN·m−1
at 32 mN m−1 pic/mN·m−1 C
−1
s, max/mN·m−1
ACMM 169.47 44.87 47.07 76.57
ACMM + PLGA-DXI-PVA-NPs 185.50 29.35 51.00 84.83
ACMM + PLGA-DXI-PEG 5%-PVA-NPs 194.17 39.89 47.72 76.77
ACMM + PLGA-DXI-PEG 10%-PVA-NPs 184.36 50.19 47.14 93.17
ACMM + PLGA-DXI-PEG 15%-PVA-NPs 197.36 60.17 45.45 96.46
ACMM + PLGA-DXI-TWEEN-NPs 234.10 28.16 46.98 45.88
ACMM + PLGA-DXI-PEG 5%-Tween-NPs 238.04 21.58 47.55 52.07
ACMM + PLGA-DXI-PEG 10%- Tween
-NPs 223.49 23.52 48.02 66.36
ACMM + PLGA-DXI-PEG 15%- Tween
-NPs 247.55 29.16 46.24 39.12
ACMM + PLGA-DXI-Lutrol-NPs 178.19 52.24 46.00 63.94
ACMM + PLGA-DXI-PEG 5%- Lutrol -NPs 186.69 47.55 47.30 96.83
ACMM + PLGA-DXI-PEG 10%- Lutrol-NPs 178.75 48.04 47.70 94.78
ACMM + PLGA-DXI-PEG 15%- Lutrol
-NPs 180.36 40.82 46.56 63.94
ACMM monolayer exhibits a LE (liquid expanded) state in the entire range of surface pressures
(Figure 7). C−1s of ACMM monolayer constantly grew until a first maximum (pi around 14 mN·m−1)
then decreased slowly (plateau between 15 and 25 mN·m−1). Afterwards, it started rising again until a
second maximum (pi around 47 mN·m−1), finally C−1s decreasing drastically because of the monolayer
collapse. This behavior has been observed for other lipid systems containing cholesterol [39,40] and it
is indicative of the changes in the packing of the monolayer during compression and clearly indicates
two membrane domain formation, a phospholipid-rich domain (low C−1s values) and a cholesterol-rich
domain (high C−1s values). This pattern is similar to other systems studied; in all cases two LE domains
appeared. Collapse pressure values are very similar and do not differ significantly from the pic
obtained for pure cholesterol monolayer (around 46 mN·m−1) [43]. This suggests some immiscibility
phenomena [43–45] according with the presence of two domains. C−1s values allow us to postulate that
PEG mainly mixes with phospholipid-rich domains. However, PEG modifications do not seem to affect
in a significant manner. Despite this, a trend towards a higher interaction as PEG increased could be
observed. On the other hand, Tween 80 clearly expanded the monolayer (more than Lutrol and PVA).
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Figure 7. Surface pressure-area (pi-A) isotherms of the ACMM monolayer and mixed ACMM–NPs_DXI_PLGA at different PEG concentrations and surfactants (A)
PVA, (B) Tween and (C) Lutrol, (D–F) respective compressibility modulus plots.
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3.6.2. Membrane Dipole Potential Changes
The dipole potential of lipid membranes is an electrical potential caused by the dipole orientation at
the membrane/water interface. As described in the literature, polar groups of phospholipid molecules,
such as ester, bond with acyl chains and glycerol groups of phospholipids. The orientation of water
molecules around the membrane is the origin of the membrane dipole potential [46]. This is a positive
potential in the bilayer and plays an important role in membrane functions, affecting the membrane
permeability and the drugs binding capacity to the membrane among others [28,47,48]. Fluorescent
probe di-8-ANEPPS is sensitive to the membrane dipole potential changes. It was used to investigate
the interaction of NPs with ACMM. Regarding the NPs composition, it is possible to evaluate the
effect of surfactant and the percentage of PEG in dipole potential changes. DXI NPs were tested
at 32 ◦C and all of them were able to reduce the membrane dipole potential. A decreasing dipole
potential suggests a shift to the red in the excitation spectra that results in a differential fluorescence
spectrum, obtained by subtracting the ACMM-liposome spectrum from that obtained for a suspension
containing ACMM-liposomes and increasing concentrations of DXI NPs. The extension of dipole
potential reduction is concentration dependent. Figure 8 shows the difference fluorescence spectra
obtained for a suspension containing ACMM-liposomes and increasing concentrations of DXI NPs
developed using Tween. The interaction of all other formulations assessed causes similar redshift
in the excitation spectra yielding a similar shape in differential fluorescence spectra. Figure 9 shows
the binding profile obtained by plotting the di-8-ANEPPS excitation normalized ratio (Rnorm) NPs
concentration (in µg·mL−1). Rnorm slightly decreased with increasing of the NPs concentration implying
a drop off on membrane lipid order. Due to the fact that from 95 µg·mL−1 the interaction of DXI
NPs and the in vitro membrane is close to saturation; the extrapolation of this results in vivo, would
ensure that the concentration added in the eye would cause the maximum interaction with the corneal
membrane, ensuring the maximum interaction of DXI NPs with the membrane. This is agreement
with pi-A results being both models in accordance. Table 5 shows the interaction parameters (Kd and
Bmax) for all formulations assayed. Kd is an index of the interaction, the lower Kd the greater interaction,
and Bmax indicates the magnitude of binding maximum. Regarding the surfactant used, the highest
interaction is associated with Tween in all the cases.
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Figure 8. Fluorescence differential spectra of di-8ANEPPS labeled ACMM large unilamellar vesicles
(LUVs) in presence of DXI NPs using Tween, at different concentrations. Before subtraction, the spectra
were normalized to the integrated areas. Lipid concentration was constant at 200 µM. All experiments
were performed in 10 mM TRIS buffer (pH 7.4) at 32 ◦C.
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Table 5. Binding parameters of PLGA DXI NPs using the fluorescence of the potential sensitive
probe di-8-ANEPPS. Kd is the apparent dissociation constant for binding NPs to ACMM and Bmax the
maximum NPs capacity to link to the membrane.
DXI NPs Bmax Kd R2
PLGA-PVA 0.55 ± 0.01 39.95 ± 3.58 0.996
PEG 5%-PVA 0.68 ± 0.01 10.93 ± 1.07 0.998
PEG 10%-PVA 0.72 ± 0.02 46.98 ± 3.85 0.997
PEG 15%-PVA 0.65 ± 0.02 18.97 ± 2.03 0.993
PLGA-Tween 0.59 ± 0.00 27.52 ± 7.37 0.960
PEG 5%-Tween 0.70 ± 0.01 5.48 ± 0.62 0.999
PEG 10%-Tween 0.59 ± 0.02 16.17 ± 2.69 0.984
PEG 15%-Tween 0.62 ± 0.02 8.86 ± 1.95 0.976
PLGA-Lutrol 0.71 ± 0.03 57.49 ± 7.08 0.993
PEG 5%-Lutrol 0.66 ± 0.00 17.82 ± 0.35 0.999
PEG 10%-Lutrol 0.65 ± 0.03 53.43 ± 7.17 0.993
PEG 15%-Lutrol 0.61 ± 0.05 10.9 6 ± 0.39 0.993
3.7. Ocular Inflam ation
Ocular inflammation is a well-documented complication of cataract surgery, causing increased
intraocular pressure, posterior-capsule opacification, cystoid macular edema and decreased visual
acuity [49]. Therefore, prevention of ocular inflammation has been studied in vivo using New
Zealand rabbits.
It can be observed that adding PEG to the formulations increases their therapeutic efficacy
probably due to the fact that it increases the penetration of the nanoparticles into the corneal epithelium
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by interpenetration and/or hydrogen bonding with the mucus [5]. Moreover, DXI NPs were able to
prevent ocular inflammation more effectively that free DXI in all the formulations [11]. In the case of
DXI NPs prepared with PVA, a difference could be observed when PEG was added but no difference
was observed as the percentage of PEG increased. In the case of PLGA NPs prepared using Tween,
their efficacy increased with PEG 10% and no difference between PEG 10% and 15% was appreciated.
On the other hand, NPs prepared using Lutrol showed the best results when either high amount
of PEG or even no PEG was applied. These results correlated with the in vitro drug release where
PLGA Lutrol NPs were able to obtain higher release values (Figure 10). These therapeutic efficacy
studies demonstrated that when the anti-inflammatory efficacy was compared using PEG, this PEG
addition was able to increase the antiinflammatory effects. Therefore, the maximum therapeutic effect
was obtained with formulations containing PEG compared with only PLGA. Moreover, the necessary
amount of PEG on the surface of the NPs for optimal permeability in the mucosa will vary depending
on different factors such as size, NPs core (in this case PLGA), the media in which NPs are dispersed,
the molecular weight of PEG and the type of mucosa with which they interact [50]. Therefore, in our
study, the differences observed using several PEG percentages obtaining greater antiinflammatory
efficacy might be due to the presence of different surfactants.
The drug release of PLGA 10% NPs using Tween shows similar values, with Tween and Lutrol
having a slightly better Lutrol drug release. However, the in vivo results demonstrated that PLGA 10%
Tween decreased the inflammation more effectively than PLGA 10% Lutrol. This correlated with the
in vitro interactions study since it shows that Tween increased membrane permeability and might lead
to the obtention of increasing antiinflammatory effects. Regarding PLGA 15%, higher amounts of DXI
in vitro were also released and the best antiinflammatory results were observed with this formulation.
Therefore, the best anti-inflammatory results were obtained with PLGA Lutrol, PLGA 5% PEG
Lutrol, PLGA 10% PEG Tween and PLGA 15% PEG using Lutrol.
In this sense, the use of Lutrol F68 as a surfactant is supported by a high number of authors for
ocular drug delivery. This may be due to the fact that it favors both the physical properties of the NPs
and, at the same time, it presents low ocular toxicology as has been demonstrated, due to the absence
of any irritating ocular phenomena even in high concentrations [51]. Moreover, this surfactant is able
to increase the anti-inflammatory efficacy of the NSAIDs formulation [52].
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Figure 10. Inflammation score obtained with the different formulations. (A) DXI PLGA NPs, (B) DXI
PLGA 5% PEG NPs, (C) DXI PLGA 10% PEG NPs and (D) DXI PLGA 15% PEG NPs (* p < 0.05,
** p < 0.01, *** p < 0.001; **** p < 0.0001) significantly different antiinflammatory effect).
3.8. Ex Vivo Permeation Assay
To reduce the number of animals, an ex vivo permeation assay was carried out using the most
effective formulations. Therefore, four formulations were assessed (DXI PLGA Lutrol NPs, DXI PLGA
5% PEG Lutrol NPs, DXI PLGA 10% Tween NPs and DXI PLGA 15% PEG Lutrol NPs). Corneal and
scleral permeation were studied (Table 6, Figure 11). All the release data were adjusted to the most
co mon kinetic equations.
In all formulations assessed, corneal DXI permeation was slightly hi er than scleral perm ation.
These results were in accordanc w th othe authors developing polymeric NPs containing NSAIDs,
which were able to promote incre sed corneal r te tion [53]. Focusing on this corneal permeation,
the best fit was ob ai ed for both PLGA and PLGA 5% PEG NPs with a Korsmeyer–Peppas equation.
In this equation, the r lease exponent values (n) a high r with PLGA 5% PEG and also the K was
higher on PLGA 5% (0.81 vs. 1.45 min). These results suggest that the addition of 5% PEG increases
corneal DXI release. At the same time, it was demonstrated using the customized corneal membrane
model that the addition of PEG slightly increased the interactions. Increasing the PEG % to 10% and
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15%, adjusted better with a hyperbola equation. Increasing PEG % also increased the amount of DXI
permeated. Moreover, it also increased the Kd, obtaining a slower release as PEG % is increased. These
results were in concordance with the in vitro drug release, where a higher amount of DXI was released
but also a longer time until it reached the equilibrium was observed.
Table 6. Ex vivo permeation pharmacokinetic parameters (n: release exponent).
Corneal Permeation
Formulation Best Fit Pharmacokinetic Parameters
PLGA Lutrol Korsmeyer-Peppas K: 0.814 ± 0.075 n: 0.33 ± 0.02
PLGA 5% Lutrol Korsmeyer-Peppas K: 1.45 ± 0.34 n: 0.40 ± 0.04
PLGA 10% Tween Hyperbola Kd: 38.01 ± 3.64 min B max: 19.8% ± 0.4904%
PLGA 15% Lutrol Hyperbola Kd: 46.02 ± 4.15 min B max 27.98% ± 0.7002%
Scleral Permeation
Formulation Best Fit Pharmacokinetic Parameters
PLGA Lutrol Korsmeyer-Peppas K: 7.29 ± 0.58 N: 0.14 ± 0.16
PLGA 5% Lutrol Hyperbola Kd: 90.92 ± 8.80 min Bmax: 24.64% ± 0.85%
PLGA 10% Tween Hyperbola Kd: 24.26 ± 3.90 min Bmax: 21.57% ± 0.75%
PLGA 15% Lutrol Hyperbola Kd: 19.23 ± 2.59 min Bmax: 23.05% ± 0.61%Nanomaterials 2020, 10, x FOR PEER REVIEW 21 of 25 
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drug delivery to the posterior eye segment. Moreover, a comparison between different surfactants 
shows that Lutrol produced the best therapeutic efficacy, which may be due to a synergistic, anti-
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Lutrol). (A) Corneal permeation; (B) Scleral permeation.
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Moreover, the results obtained correlate with other studies such as the investigation carried out by
Giannavola and colleagues where they demonstrated that PEGylation of polymeric NPs using PLA as
the core polymer, increased drug permeation through the corneal tissue [54]. Moreover, they obtained
higher drug values in aqueous humor with PEGylated NPs than with NPs without PEG.
Regarding the scleral permeation, PLGA NPs were able to permeate more efficiently through
the cornea than through the sclera showing a certain corneal tropism. On the other hand, PLGA 5%
PEG permeated slightly better through the scleral tissue. Adding more PEG marginally increased
scleral permeation but significantly increased corneal values. These results were in agreement with the
results obtained using the customized lipid model. All the formulations with PEG were adjusted to a
Hyperbola equation, obtaining lower Kd as the PEG % increased (faster release of the drug).
Therefore, it is worth noting by observing the results of ex vivo permeation studies that
nanoparticles with the presence of PEG have great potential to increase ocular bioavailability in
the anterior segment of the eye, such as the cornea, conjunctiva or aqueous humor. Therefore, the
use of PEGylated NPs will require a lower dosing frequency, allowing the mucin to retain a higher
concentration of DXI. This may indicate that the patients will follow a better compliance with the
treatment, which will be translated into greater therapeutic efficacy [55].
4. Conclusions
DXI, the active enantiomer of ibuprofen, encapsulated in biodegradable PLGA nanoparticles,
constituted a suitable strategy to prevent corneal inflammation, associated with procedures such as
cataract surgery. Interaction studies of DXI NPs using different surfactants and PEG amounts were
carried out using a customized in vitro membrane model. Using this model, it was observed that DXI
NPs were able to interact with the membrane in an effective manner in all cases. However, Tween 80
could expand the membrane by potentially increasing its permeability, which could be useful for drug
delivery to the posterior eye segment. Moreover, a comparison between different surfactants shows
that Lutrol produced the best therapeutic efficacy, which may be due to a synergistic, anti-inflammatory
effect being elicited [56]. It has also shown a favorable interaction with the developed membrane
model. Moreover, increasing the amount of PEG constitutes an effective strategy to increase corneal
drug delivery without causing irritation of the ocular tissues.
In conclusion, the formulations containing DXI PLGA 15% PEG prepared using Lutrol as a
surfactant were able to release DXI more effectively for the treatment of ocular inflammation. The
development of an in vitro membrane model constitutes an interesting strategy in order to correlate
in vitro, ex vivo and in vivo results and, in further experiments, reduce the number of animals required.
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